Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Archives of Biochemistry and Biophysics

• Publication date

  1996-09-15

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1006/ABBI.1996.0414PMID 8809086
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Three-dimensional quantitative structure-activity relationship for inhibitors of cytochrome P4502C9.

  1996cited by this paper
• P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature.

  1996cited by this paper
• A 2.4-megabase physical map spanning the CYP2C gene cluster on chromosome 10q24.

  1995cited by this paper
• Cytochromes P450 expression systems.

  1995cited by this paper
• Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese.

  1995cited by this paper
• Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy.

  1995cited by this paper
• Cytochrome P450 2A1, 2E1, and 2C9 cDNA-expression by insect cells and partial purification using hydrophobic chromatography.

  1995cited by this paper
• Selectivity of flavin-containing monooxygenase 5 for the (S)-sulfoxidation of short-chain aralkyl sulfides.

  1995cited by this paper
• Molecular cloning, expression and characterization of an endogenous human cytochrome P450 arachidonic acid epoxygenase isoform.

  1995cited by this paper
• Prochiral sulfides as in vitro probes for multiple forms of the flavin-containing monooxygenase.

  1995cited by this paper
• Role of cytochrome P450 2C9 and an allelic variant in the 4'-hydroxylation of (R)- and (S)-flurbiprofen.

  1995cited by this paper
• Structure and function of cytochromes P450: a comparative analysis of three crystal structures.

  1995cited by this paper
• Altering the regiospecificity of androstenedione hydroxylase activity in P450s 2a-4/5 by a mutation of the residue at position 481.

  1995cited by this paper
• Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9.

  1994cited by this paper
• Biochemistry and molecular biology of the human CYP2C subfamily.

  1994cited by this paper
• Alterations of the regiospecificity of progesterone metabolism by the mutagenesis of two key amino acid residues in rabbit cytochrome P450 2C3v.

  1994cited by this paper
• Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans.

  1994cited by this paper
• cDNA-directed expression of human cytochrome P450 CYP3A4 using baculovirus.

  1994cited by this paper
• Engineering of cytochrome P450 2B1 specificity. Conversion of an androgen 16 beta-hydroxylase to a 15 alpha-hydroxylase.

  1993cited by this paper
• Predicting the cytochrome P450 mediated metabolism of xenobiotics.

  1993cited by this paper
• Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily.

  1993cited by this paper
• Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe.

  1993cited by this paper
• A major role for cytochrome P450TB (CYP2C subfamily) in the actions of non-steroidal antiinflammatory drugs.

  1993cited by this paper
• Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions.

  1992cited by this paper
• Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences.

  1992cited by this paper
• The human hepatic cytochromes P450 involved in drug metabolism.

  1992cited by this paper
• In vitro oxidation of oxicam NSAIDS by a human liver cytochrome P450.

  1992cited by this paper
• Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily.

  1991cited by this paper
• Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9.

  1991cited by this paper
• Stereoselective sulfoxidation of a series of alkyl p-tolyl sulfides by microsomal and purified flavin-containing monooxygenases.

  1990cited by this paper
• Intrinsic isotope effects suggest that the reaction coordinate symmetry for the cytochrome P-450 catalyzed hydroxylation of octane is isozyme independent.

  1990cited by this paper
• Molecular genetics of the P-450 superfamily.

  1990cited by this paper
• Evolution of the P450 gene superfamily: animal-plant 'warfare', molecular drive and human genetic differences in drug oxidation.

  1990cited by this paper
• Characteristics of warfarin hydroxylation catalyzed by human liver microsomes.

  1989cited by this paper
• Novel exogenous heme-dependent expression of mammalian cytochrome P450 using baculovirus.

  1989cited by this paper
• Expression of a human liver cytochrome P-450 protein with tolbutamide hydroxylase activity in Saccharomyces cerevisiae.

  1989cited by this paper
• Human cytochrome P-450 PB-1: a multigene family involved in mephenytoin and steroid oxidations that maps to chromosome 10.

  1988cited by this paper
• Characterization of cDNAs, mRNAs, and proteins related to human liver microsomal cytochrome P-450 (S)-mephenytoin 4'-hydroxylase.

  1988cited by this paper
• cDNA and amino acid sequences of two members of the human P450IIC gene subfamily.

  1987cited by this paper
• Nucleotide sequence of a human liver cytochrome P-450 related to the rat male specific form.

  1987cited by this paper
• The warfarin‐sulfinpyrazone interaction: stereochemical considerations

  1986cited by this paper
• DNA sequencing with chain-terminating inhibitors.

  1977cited by this paper
• Warfarin. Stereochemical aspects of its metabolism and the interaction with phenylbutazone.

  1974cited by this paper

• Association of VKORC1 and CYP2C9 gene polymorphisms with warfarin dose requirements in a representative Iranian population with cardiac valve replacement surgery.

  2025cites this paper
• Warfarin Pharmacogenomics in the Era of Precision Medicine: Persistent Underrepresentation of Non-European Ancestries and Implications for Global Health Equity

  2025cites this paper
• A genome-wide association study of plasma concentrations of warfarin enantiomers and metabolites in sub-Saharan black-African patients

  2022cites this paper
• Pharmacokinetic Modeling of Warfarin ІI – Model-Based Analysis of Warfarin Metabolites after Warfarin Administered Either Alone or Together with Fluconazole or Rifampin

  2022influential citation
• Human Cytochrome P450 2C9 and its Polymorphic Modifications: Electroanalysis, Catalytic Properties and Approaches to the Regulation of Enzymatic Activity

  2022cites this paper
• Ethnic Diversity and Warfarin Pharmacogenomics

  2022cites this paper
• Establishment of prediction algorithm for the Honghe minority group based on warfarin maintenance dose.

  2022cites this paper
• Frequency of Important CYP450 Enzyme Gene Polymorphisms in the Iranian Population in Comparison with Other Major Populations: A Comprehensive Review of the Human Data

  2021cites this paper
• Engineered human CYP2C9 and its main polymorphic variants for bioelectrochemical measurements of catalytic response.

  2020cites this paper
• Antikoagülan tedavisi alan hastalarda CYP2C9 gen polimorfizminin araştırılması

  2020cites this paper
• Influence of genotype on warfarin dose requirements-a systematic review and meta-analysis

  2020cites this paper
• Heterologous Expression and Functional Characterization of Novel CYP2C9 Variants Identified in the Alaska Native People

  2020cites this paper
• Dapsone activation of CYP2C9 allelic variants

  2020influential citation
• Type : Article Enantiospecific pharmacogenomics of fluvastatin

  2019cites this paper
• Calling Star Alleles With Stargazer in 28 Pharmacogenes With Whole Genome Sequences

  2019cites this paper
• The Impact of CYP2C9 and VKORC1 Polymorphism in Patient’s Response to Warfarin and Acenocoumarol

  2019cites this paper
• Pharmacogenetics of anticoagulants used for stroke prevention in patients with atrial fibrillation

  2019cites this paper
• PHARMACOGENETIQUE DE L’ACENOCOUMAROL : LES GENES IMPLIQUES DANS LA VARIABILITE DE LA REPONSE ET PROPOSITION D’UN ALGORITHME PREDICTIF DE LA DOSE POUR LA POPULATION MAROCAINE

  2019cites this paper
• Enantiospecific Pharmacogenomics of Fluvastatin

  2019cites this paper
• Genetic Factors Influencing Warfarin Dose in Black‐African Patients: A Systematic Review and Meta‐Analysis

  2019cites this paper
• Clinical And Pharmacogenetic Determinants Of Plasma Factor Xa Inhibitor Systemic Exposure

  2018cites this paper
• Pharmacogenetics of Adverse Drug Reactions.

  2018cites this paper
• Molecular simulation study of CYP2B6 polymorphism with and without psoralen

  2018cites this paper
• Effect of genetic and patient factors on warfarin pharmacodynamics following warfarin withdrawal: Implications for patients undergoing surgery.

  2018cites this paper
• Pharmacogenomics of CYP2C9: Functional and Clinical Considerations†

  2017cites this paper
• Genotyping of CYP2C9 and VKORC1 polymorphisms predicts south Indian patients with deep vein thrombosis as fast metabolizers of warfarin/acenocoumarin.

  2017cites this paper
• CYP2C9 Genotype‐Dependent Warfarin Pharmacokinetics: Impact of CYP2C9 Genotype on R‐ and S‐Warfarin and Their Oxidative Metabolites

  2017cites this paper
• Risk of development of hemorrhagic complications due to warfarin therapy

  2017cites this paper
• High allele frequency of CYP2C9*3 (rs1057910) in a Negrito’s subtribe population in Malaysia; Aboriginal people of Jahai

  2016cites this paper
• Oral anticoagulation: a critique of recent advances and controversies.

  2015cites this paper
• Genetic Polymorphism of Cytochrome p450 (2C9) Enzyme in Iranian Baluch Ethnic Group

  2015cites this paper
• Genetic determinants of response to aspirin and warfarin and development of silicon nanowire based genotyping

  2015cites this paper
• Genetic Variations in the Xenobiotic-Metabolizing Enzymes CYP1A1, CYP1A2, CYP2C9, CYP2C19 and Susceptibility to Colorectal Cancer Among Turkish People

  2014cites this paper
• Farmacogenetica dei farmaci antiepilettici

  2014cites this paper
• Association between cytochrome P450 2C9 gene polymorphisms and colorectal cancer susceptibility: evidence from 16 case–control studies

  2014cites this paper
• Effect of CYP2D6, CYP2C9 and ABCB1 genotypes on fluoxetine plasma concentrations and clinical improvement in children and adolescent patients

  2014cites this paper
• CYP2C0, VKORC1 and CYP4F2 Variant Frequencies in Patients on either Low or High Stable Warfarin Maintenance Therapy in the Ghanaian Population

  2014cites this paper
• Pharmacogenomics of Warfarin

  2014cites this paper
• Mechanisms of Adverse Drug Reactions

  2014cites this paper
• Drug Response Heterogeneity and the Genetic Variability of Cytochrome P450–Metabolizing Enzymes

  2014cites this paper
• Functional effects of cytochrome P450 variants on drug metabolism and adverse drug reactions: developing and extending high throughput P450 protein technology platforms

  2014cites this paper
• Genetic variation inUGTgenes modify the associations of NSAIDs with risk of colorectal cancer: Colon cancer family registry: Genetic Variants inUgtandCyp2c9, Nsaid Use and Colorectal Cancer Risk

  2014cites this paper
• Pharmacokinetics in children with liver disease : can ex vivo obtained population-specific CYP450 characteristics bridge the knowledge gap?

  2014cites this paper
• Pharmacogenetic biomarkers for predicting drug response

  2014cites this paper
• Pharmacogénétique des médicaments antiépileptiques

  2014cites this paper
• Genetic variation in UGT genes modify the associations of NSAIDs with risk of colorectal cancer: Colon cancer family registry

  2014influential citation
• p-Aminothiophenol modification on gold surface improves stability for electrochemically driven cytochrome P450 microsome activity

  2014cites this paper
• Adherence and variability in warfarin dose requirements: assessment in a prospective cohort.

  2013cites this paper
• Pharmacogenetics of Oral Anticoagulants

  2013cites this paper
• Genetic and Environmental Factors

  2013cites this paper
• Metabolism of R- and S-warfarin by CYP2C19 into four hydroxywarfarins.

  2013cites this paper
• Genetic and pharmacogenetic determinants of cardiovascular disease

  2013cites this paper
• Pharmacogenetic predictors of taxane-induced peripheral neuropathy

  2013cites this paper
• Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms

  2013cites this paper
• interindividual variability in the dose-anticoagulant effect of warfarin A polymorphism in the VKORC1 gene is associated with an

  2013cites this paper
• Quantitative Assessment of the Effect of Cytochrome P450 2C9 Gene Polymorphism and Colorectal Cancer

  2013cites this paper
• Expanding Role of Pharmacogenomics in the Management of Cardiovascular Disorders

  2013cites this paper
• A systematic review on pharmacogenetics in cardiovascular disease Is it ready for clinical application ?

  2013cites this paper
• Drug Interactions, Pharmacogenomics and Cardiovascular Complication

  2013cites this paper
• Genetics of the Response to Antithrombotic Drugs and the Need for Monitoring

  2012cites this paper
• Pharmacogenomics Aspect of Warfarin Therapy

  2012cites this paper
• Effect of Genetic Variants, Especially CYP2C9 and VKORC1, on the Pharmacology of Warfarin

  2012cites this paper
• Development of an In Vitro System with Human Liver Microsomes for Phenotyping of CYP2C9 Genetic Polymorphisms with a Mechanism-Based Inactivator

  2012cites this paper
• Determinants of adverse events during oral anticoagulant treatment

  2012cites this paper
• Pharmacogenetics in Drug Metabolism: Role of Phase I Enzymes

  2012cites this paper
• This material is the copyright of the original publisher. Unauthorised copying and distribution is prohibited. A Pharmacokinetic-Pharmacodynamic Model for Predicting the Impact of CYP2C9 and VKORC1 Polymorphisms on Fluindione and Acenocoumarol During Induction Therapy

  2012cites this paper
• Evaluation of the effect of genetic variations in GATA-4 on the phenprocoumon and acenocoumarol maintenance dose.

  2012cites this paper
• Personalized approach of medication by indirect anticoagulants tailored to the patient—Russian context: what are the prospects?

  2012cites this paper
• Prooxidant properties of ascorbic acid in the nigrostriatal dopaminergic system of C57BL/6 mice.

  2012cites this paper
• A Pharmacokinetic-Pharmacodynamic Model for Predicting the Impact of CYP2C9 and VKORC1 Polymorphisms on Fluindione and Acenocoumarol During Induction Therapy

  2012cites this paper
• Decreased Warfarin Clearance Associated With the CYP2C9 R150H (*8) Polymorphism

  2012cites this paper
• Anticoagulation par antivitamines K: analyse des interactions médicamenteuses et des polymorphismes génétiques à l'origine de la variabilité de la réponse et des risques liés à l'acénocoumarol

  2012cites this paper
• Selective filling of nanowells in nanowell arrays fabricated using polystyrene nanosphere lithography with cytochrome P450 enzymes

  2012cites this paper
• CYP2C9 gene polymorphisms and warfarin dose requirement: a single-center experience in Turkey

  2012cites this paper
• Prevalence of VKORC1 and CYP2C9 gene polymorphisms in Indian population and its effect on warfarin response.

  2012cites this paper
• Decreased Warfarin Clearance with the CYP 2 C 9 R 150 H ( * 8 ) Polymorphism

  2012cites this paper
• Genetic variation in the CYP2C monooxygenase enzyme subfamily shows no association with longevity in a German population.

  2011cites this paper
• Enzyme-based amperometric platform to determine the polymorphic response in drug metabolism by cytochromes P450.

  2011cites this paper
• Pre-clinical metabolism studies with Fenretinide in paediatric cancer

  2011cites this paper
• An expanded, unified substrate recognition site map for mammalian cytochrome P450s: analysis of molecular interactions between 15 mammalian CYP450 isoforms and 868 substrates.

  2011cites this paper
• Genetics of Warfarin Sensitivity in an Emergency Department Population with Thromboembolic

  2011cites this paper
• Genetics of Warfarin Sensitivity in an Emergency Department Population with Thromboembolic

  2011cites this paper
• Controversies in cardiovascular medicine A systematic review on pharmacogenetics in cardiovascular disease : is it ready for clinical application ?

  2011cites this paper
• Polymorphisms of human cytochrome P450 2C9 and the functional relevance.

  2010cites this paper
• Comparison of enzyme kinetic parameters obtained in vitro for reactions mediated by human CYP2C enzymes including major CYP2C9 variants.

  2010cites this paper
• The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients.

  2010cites this paper
• Pharmacogenetic Impact of VKORC1 and CYP2C9 Allelic Variants on Warfarin Dose Requirements in a Hispanic Population Isolate

  2010cites this paper
• Pharmacogenetics of cytochrome P450 (CYP) in the elderly.

  2010cites this paper
• Polymorphisms in xenobiotic metabolizing enzymes and diet influence colorectal adenoma risk

  2010cites this paper
• Some non-heterocyclic polycyclic aromatic hydrocarbons and some related exposures.

  2010cites this paper
• Warfarin Toxicity and Individual Variability—Clinical Case

  2010cites this paper
• Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups.

  2010cites this paper
• Genetic variants of flavin-containing monooxygenases:consequences for drug metabolism

  2010cites this paper
• Influence du chondroïtine sulfate (CS) sur l’activité et l’expression de plusieurs isoformes du cytochrome P450 et de la NADPH P450 réductase

  2010cites this paper
• Oxidative biotransformation of fatty acids by cytochromes P450: predicted key structural elements orchestrating substrate specificity, regioselectivity and catalytic efficiency.

  2010cites this paper
• Drug interactions with antiretrovirals and warfarin

  2010cites this paper
• New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part II.

  2009cites this paper
• Implications of pharmacogenetics for oral anticoagulants metabolism.

  2009cites this paper
• Assessing cytochrome P450 and UDP-glucuronosyltransferase contributions to warfarin metabolism in humans.

  2009cites this paper
• Expression and Functional Analysis of CYP2D6.24, CYP2D6.26, CYP2D6.27, and CYP2D7 Isozymes

  2009cites this paper